The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Urges everyone to follow COVID Appropriate Behaviour and curb any misinformation
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Subscribe To Our Newsletter & Stay Updated
